Decreased lymphocyte blastogenesis, IL2 production and NK activity following nifedipine administration to healthy humans

A. Morgano, I. Pierri, R. Stagnaro, M. Setti, F. Puppo, F. Indiveri

Research output: Contribution to journalArticle

Abstract

The effects of a single oral dose of nifedipine on part of the immune response in healthy humans has been investigated in terms of two different immune functions: T lymphocyte proliferation and NK activity. Both functions are known to require calcium ions. Ten healthy subjects were bled before and 30 min, and 4 and 24 h after receiving 10 mg nifedipine. Lymphocyte proliferation, both in mitogen-activated lymphocyte cultures, and in autologous and allogeneic mixed lymphocyte reactions, was significantly reduced (up to 48%) 30 min after drug administration and reverted to normal 4 h later. The inhibition could be attributed to reduction in IL2 production by the T cells isolated 30 min following the administration of nifedipine, since they normally express IL2-receptors. The addition of recombinant IL2 of 200 U·ml-1 to the cell cultures restored their responsiveness. NK activity was significantly reduced 30 min and 4 h after drug administration and returned to normal at the 24th h. This function was also restored by the addition of IL2. The data suggest that calcium channel blockers may inhibit, at least transiently, lymphocyte functions in vivo.

Original languageEnglish
Pages (from-to)545-550
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Volume39
Issue number6
DOIs
Publication statusPublished - Dec 1990

Keywords

  • calcium channel blockers
  • interleukin-2
  • lymphocyte function
  • Nifedipine
  • NK activity
  • T-cell proliferation

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Decreased lymphocyte blastogenesis, IL2 production and NK activity following nifedipine administration to healthy humans'. Together they form a unique fingerprint.

  • Cite this